Open Innovation in the Pharmaceutical Industry: An Empirical Analysis on Context Features, Internal R&D, and Financial Performances

Abstract

This paper aims at investigating the relationships between the adoption of open innovation by companies and their context features, internal R&D, and financial performances. Two proxies for openness-variety and intensity-are defined, and six hypotheses are formulated and tested on a sample of 68 worldwide top R&D spending pharmaceutical companies. The period of 2008-2012 was analyzed for a total of 340 statistical units. Our results suggest that open innovation is a very pervasive behavior among smaller and younger companies, for which internal R&D is complementary to openness; still being in the development phase, they derive most of their revenues from open innovation itself and show negative financial performances. Yet, a wider range of open transactions are performed by larger and longer established firms, exhibiting good financial performances and adopting open innovation as a substitution to internal R&D efforts. Through an in-depth review of the literature, this paper contributes to the research on open innovation by providing an accounting measurement system, testing six hypotheses among open innovation and some firm-level variables, and positioning the obtained results within the current debate.

Cite this work

No public copy is stored for this record, so only the metadata is cited.

Stored only when both papers are in the corpus — 39 citations exist upstream.

Papers that cite the same references — the relational fallback while embeddings are still backfilling.